Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piroxini (XZP-3287) plus letrozole or anastrozole versus placebo plus letrozole or anastrozole in HR-positive, HER2-negative advanced breast cancer
CTR20220212Phase 3Active
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bireociclib, sponsored by Xuanzhu Biopharmaceutical. Started Mar 2022; status: active.
02
Drugs
bireociclib
Beyond the preview
Go deeper on CTR20220212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220212.